Silica nanoparticles in nanomedicine: Evolution from synthesis control to biological identity, clearance-aware design, and translation: A fundamental review

Silica nanoparticles (SNPs) have developed from simple colloidal and reporter-protection systems into diverse nanomedicine platforms for molecular confinement, controlled drug and nucleic-acid delivery, imaging and sensing, immunomodulation, and local or regenerative treatment. Despite this breadth, silica nanomedicine is still commonly reviewed by architecture, surface modification, or application. That organization catalogs innovation but does not consistently explain how synthesis chemistry creates the material state that ultimately governs biological identity, function, persistence, and translation. This fundamental Review addresses that gap by integrating a problem–solution–liability–evidence logic with a process–structure–interface–fate continuum. The evolution from dense Stöber colloids to mesoporous, hollow, dendritic, hybrid, organosilica, and ultrasmall core–shell systems is therefore examined as a sequence of mechanistic responses to specific constraints in cargo access, colloidal stability, biological recognition, intracellular release, and elimination. Particular attention is given to framework condensation, silanol accessibility, hydrated pore structure, surface coverage, aggregation, protein-corona formation, degradation, and silicon clearance because these attributes connect reaction history to the state actually encountered in biological media. Applications are treated as mechanistic stress tests rather than as a catalogue: oral and systemic delivery, nucleic-acid delivery, oncology, imaging and sensing, and local or regenerative uses are evaluated according to the distinctive function supplied by silica and the liabilities introduced by that function. The evidence shows that dry-state architecture alone is an insufficient predictor of nanomedicine performance; degradation, fragmentation, urinary reporter recovery, and whole-body elimination are also distinct endpoints. Human evidence remains strongest for ultrasmall imaging probes, whereas conventional systemically administered mesoporous and multifunctional therapeutic constructs remain predominantly preclinical. The Review therefore establishes a fundamental basis for linking synthesis-derived material identity to biological function, clearance, pharmaceutical critical quality attributes, and clinically relevant design.